To read the full story, subscribe or sign in.

Shionogi expands reach of COVID-19 antiviral, Xocova, to Korea and China

Jan. 10, 2023

After receiving approval in Japan for its orally administered COVID-19 antiviral, 3CL protease inhibitor Xocova (ensitrelvir/S-217622) in late November, Shionogi & Co. Ltd. is gearing up for approvals in South Korea and China.

BioWorld Asia Regulatory Asia-Pacific Japan

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 3, 2022.

Setpoint Medical - vagus nerve stimulation device

Setpoint Medical lands up to $145M to advance RA implant

BioWorld MedTech

Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...

Brain with clock hands, day and night background

12-Hour as well as circadian brain rhythms disrupted in people with schizophrenia

BioWorld Science

Research shows that individuals with schizophrenia have abnormal gene expression patterns in their brains compared with people without the condition. In a study...

Upgrade your daily dose of biopharma and medtech news

Shionogi expands reach of COVID-19 antiviral, Xocova, to Korea and China